RT Journal Article
SR Electronic
T1 SHP2 Inhibition May Resensitize NSCLC Tumors to ALK Inhibitors
JF Cancer Discovery
JO Cancer Discov
FD American Association for Cancer Research
SP OF10
OP OF10
DO 10.1158/2159-8290.CD-RW2018-043
VO 8
IS 5
YR 2018
UL http://cancerdiscovery.aacrjournals.org/content/8/5/OF10.abstract
AB Targeting SHP2 suppresses ALK inhibitor resistance caused by tyrosine kinase reactivation.